Postoperative Inotrope and Vasopressor Use Following CABG: Outcome Data from the CAPS‐Care Study

Abstract  Background/Aim: Limited clinical data exist to guide practice patterns and evidence‐based use of inotropes and vasopressors following coronary artery bypass grafting (CABG). Methods: Contemporary Analysis of Perioperative Cardiovascular Surgical Care (CAPS‐Care) collected detailed perioperative data from 2390 CABG patients between 2004 and 2005 at 55 U.S. hospitals. High‐risk elective or urgent CABG patients were eligible for inclusion. We stratified participating hospitals into high, medium, and low tertiles of inotrope use. Hospital‐level outcomes were compared before and after risk adjustment for baseline characteristics. Results: Hospital‐level risk‐adjusted rates of any inotrope/vasopressor use varied from 100% to 35%. Hospitals in the highest tertile of use had more patients with mitral regurgitation compared to medium‐ or low‐use hospitals (p < 0.001), more previous cardiovascular interventions (p = 0.002), longer cardiopulmonary bypass (p < 0.001), longer cross‐clamp times (p < 0.001), and required more transfusions (p = 0.001). Despite these differences, unadjusted outcomes were similar between high‐, medium‐, and low‐use hospitals for operative mortality (4.5% vs. 5.3% vs. 5.2%; p = 0.702), 30‐day mortality (4.1% vs. 4.6% vs. 5.0%; p = 0.690), postoperative renal failure (7.2% vs. 9.2% vs. 6.6%; p = 0.142), atrial fibrillation (23.0% vs. 27.2% vs. 25.6%; p = 0.106), and acute limb ischemia (0.6% vs. 0.5% vs. 0.5%; p = 0.945). These similar outcomes persisted after risk adjustment: adjusted OR = 0.97 (95% CI [0.94, 1.00], p = 0.086) for operative mortality and adjusted OR = 1.00 (95% CI [0.96, 1.04], p = 0.974) for postoperative renal failure. Conclusion: While considerable variability is present among hospitals in inotrope use following CABG, observational comparison of outcomes did not distinguish a superior pattern; thus, randomized prospective data are needed to better guide clinical practice. (J Card Surg 2011;26:572‐578)

[1]  E. DeLong,et al.  Secondary Prevention After Coronary Artery Bypass Graft Surgery: Findings of a National Randomized Controlled Trial and Sustained Society-Led Incorporation Into Practice , 2011, Circulation.

[2]  B. Geršak,et al.  Early extubation and fast-track anesthetic technique for endoscopic cardiac surgery. , 2010, The heart surgery forum.

[3]  E. Peterson,et al.  Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons. , 2009, American heart journal.

[4]  Chad M. House,et al.  Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB) , 2009, Journal of cardiothoracic surgery.

[5]  Sean M. O'Brien,et al.  Comparison of cardiac surgery volumes and mortality rates between the Society of Thoracic Surgeons and Medicare databases from 1993 through 2001. , 2007, The Annals of thoracic surgery.

[6]  C. Spies,et al.  Current practice of hemodynamic monitoring and vasopressor and inotropic therapy in post‐operative cardiac surgery patients in Germany: results from a postal survey , 2007, Acta anaesthesiologica Scandinavica.

[7]  M. Borger,et al.  Predictors of Low Cardiac Output Syndrome After Isolated Aortic Valve Surgery , 2005, Circulation.

[8]  B. Vallet,et al.  French multicentre survey on the use of inotropes after cardiac surgery , 2005, Critical care.

[9]  R. Bellomo,et al.  Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery – a systematic literature review , 2004, Critical care.

[10]  E. Peterson,et al.  Validity of the Society of Thoracic Surgeons National Adult Cardiac Surgery Database. , 2004, The Annals of thoracic surgery.

[11]  R. Allman,et al.  Alabama Coronary Artery Bypass Grafting Project: Results From Phase II of a Statewide Quality Improvement Initiative , 2004, Annals of surgery.

[12]  D. Nelson,et al.  Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease , 2003, Circulation.

[13]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[14]  M. Kikura,et al.  The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting. , 2002, Anesthesia and analgesia.

[15]  N. Gravenstein,et al.  Effects of milrinone versus epinephrine on grafted internal mammary artery flow after cardiopulmonary bypass. , 2000, Journal of cardiothoracic and vascular anesthesia.

[16]  J. Hammon,et al.  Factors That Predict the Use of Positive Inotropic Drug Support After Cardiac Valve Surgery , 1998, Anesthesia and analgesia.

[17]  G. Gravlee,et al.  Preoperative and Intraoperative Predictors of Inotropic Support and Long‐Term Outcome in Patients Having Coronary Artery Bypass Grafting , 1991, Anesthesia and analgesia.